MADELINE EL-GHOUL: Open Payments
NPI 1437718699 · IJAMSVILLE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,141 in 55 payments from 14 companies in 2025. Trend: 2023 $2,281 · 2024 $2,369 · 2025 $1,141
Food & beverage: $1,141
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 11 | $210 |
| AstraZeneca Pharmaceuticals LP | 10 | $199 |
| Lilly USA, LLC | 6 | $134 |
| Novo Nordisk Inc | 5 | $117 |
| GlaxoSmithKline, LLC. | 5 | $113 |
| PFIZER INC. | 4 | $87 |
| Amgen Inc. | 3 | $63 |
| Astellas Pharma US Inc | 2 | $49 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $41 |
| Xeris Pharmaceuticals, Inc. | 2 | $38 |
Products named: AIRSUPRA, QULIPTA, MOUNJARO, Ozempic, TRELEGY ELLIPTA, UBRELVY, NURTEC ODT, Veozah.
Industry payments across MD — which companies pay providers there.
